生物利用度
药理学
甲苯嗪
化学
塔克林
效力
口服
胡椒碱
医学
氯胺酮
生物化学
麻醉
酶
乙酰胆碱酯酶
体外
作者
Chuang Xia,Jiapeng He,Kai-Wen Feng,Lu Liu,Lei Zheng,Haitao Wang,Jiangping Xu,Zhong‐Zhen Zhou
标识
DOI:10.1021/acschemneuro.1c00762
摘要
To realize PDE4 inhibitors with good developmental potentiality for the treatment of dementia, structure-based optimizations of lead compound FCPR03 resulted in novel aminophenylketones 9c and 9H with low nanomolar potency, which displayed comparable activity to rolipram, satisfactory bioavailability (F% = 36.92 and 42.96% respectively), and good blood–brain barrier (BBB) permeability switching from the cyclopropyl methoxy group to the cyclopropyl methylamine and the amide group to the corresponding ketone. Emetogenicity evaluation on a combined ketamine/xylazine anesthesia mice alternative model demonstrated that 9H displays no emetogenicity even at an oral dose of 5 mg/kg. In contrast, rolipram and roflumilast displayed emetogenicity at an oral dose of 0.5 mg/kg. In acute toxicological evaluation, 9H showed no obvious toxicological effect on mice when administered at oral doses below 625 mg/kg. Further investigations revealed that 9H improves the memory and cognitive impairment of Alzheimer's disease (AD) model mice induced by Aβ25–35.
科研通智能强力驱动
Strongly Powered by AbleSci AI